SCHEMBL7148544

SCHEMBL7148544

O=C(c1ccc(F)cc1)[C@@H]1C[C@@H](S)CN1S(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 10/20 0.55
MME P08473 2/20 0.55
ACE P12821 2/20 0.55
GPR183 P32249 1/20 0.43
AKR1C3 P42330 3/20 0.43
AKR1C1 Q04828 1/20 0.42
LMNA P02545 3/20 0.41
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
ALOX12 P18054 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
HPGD P15428 1/20 0.41
MCOLN3 Q8TDD5 2/20 0.41
TSHR P16473 1/20 0.41
EIF2AK3 Q9NZJ5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7148549 1.00 ECE1 (0.55) ECE1MMEACEGPR183AKR1C3
SCHEMBL7136604 0.91 ECE1 (0.59) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7151710 0.91 ECE1 (0.59) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7137844 0.88 ECE1 (0.56) ECE1MMEACELMNAALDH1A1
SCHEMBL7137852 0.88 ECE1 (0.56) ECE1MMEACELMNAALDH1A1
SCHEMBL6977959 0.83 ECE1 (0.62) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7141433 0.83 ECE1 (0.62) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL5722920 0.83 ECE1 (0.58) ECE1MMEACELMNASMN1; SMN2
SCHEMBL7148134 0.82 ECE1 (0.64) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL5404147 0.82 ECE1 (0.61) ECE1MMEACEAKR1C3AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed